ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL

Shorter time from leukapheresis to infusion of axi-cel corresponds to better CR and OS in r/r LBCL patients

ASH 2022: Multiple myeloma roundup

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL

PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival compared to Tac/MTX in graft-versus-host disease 

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma

Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients having a suboptimal response to ruxolitinib

Consolidation therapy with blinatumomab improves OS in newly diagnosed patients with B-Lineage ALL in MRD negative remission

PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning

Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response in previously untreated CLL enriched for high-risk disease

An analysis of the worldwide utilisation of haematopoietic stem cell transplantation for acute myeloid leukaemia

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in R/R follicular lymphoma

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma

Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows promising results in patients with multiple myeloma